Potential Parkinsons Disease Treatment, A Colorado Company Set to Research This Alternative Option

Potential Parkinsons Disease Treatment, A Colorado Company Set to Research This Alternative Option


Cannabis products  have received mixed opinions over the years because of the controversy behind the legality of cannabis. But it’s also no secret that these products have been quite useful in helping to alleviate the symptoms of some chronic medical conditions including Alzheimer’s disease, seizures, epilepsy, multiple sclerosis, and chronic pain.

Colorado-based company Day Three Labs believes that there’s more potential for cannabis products to be used in the medical field. That is why it recently announced plans to research cannabis as a potential treatment for Parkinson’s disease.

Understanding Parkinson’s disease

The World Health Organization defines Parkinson’s disease as “a degenerative condition of the brain associated with motor symptoms (slow movement, tremor, rigidity, and imbalance) and other complications including cognitive impairment, mental health disorders, sleep disorders, and pain and sensory disturbances.”

Affecting more than 10 million people worldwide, Parkinson’s disease has been very difficult to manage, especially since there’s still no known cure for it. This is why the prevalence rate of this disease has doubled in the last 25 years and it  caused 329,000 deaths in 2019  alone, a 100% increase since 2000.

In 2020, a study published by the Journal of Parkinson’s disease revealed that 10% of patients in Germany suffering from Parkinson’s disease use cannabis products to treat their symptoms. This is because cannabis has been approved for use in medical treatment in the country since 2017.

However, the challenge here is the almost endless list of marijuana strains and cannabis products that make it very hard to determine which ones work or not. This is where Three Day Labs comes in, a company that specializes in the development and commercialization of cannabis products.

It’s also the only company to pass the first phase of the CanNegev program, an Israeli-funded cannabis technology incubator. This has allowed the company to receive funding for the second phase of its program involving research and data collection, which it will present in September this year at the Israel Innovation Authority.

Day Three Labs aims to study cannabis compounds using its proprietary Unlokt technology that will determine its potential as a treatment for the symptoms of Parkinson’s disease. With the right funding from the incubator, the company will be able to find the right combination of compounds to use for product development.

Dr. Shimon Lecht, Chief Innovation Officer at Day Three Labs explained: “Research shows that cannabis has the ability to ease Parkinson’s symptoms in patients, but to date, no one has

The mission to put cannabis products on center stage

Day Three Labs has always been on a mission to explore the benefits of using cannabis products to treat different medical conditions. This program is just the first step to achieving that goal.